A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

NCT Number	NCT07676266
Lead Sponsor	The Affiliated Hospital of Qingdao University Collaborators: Shanghai AbelZeta Ltd.
Conditions	Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus, Systemic Sclerosis, Immune-Mediated Necrotizing Myopathy
Enrollment	18 participants
Start Date	2026-07
Primary Completion	2027-11 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-30